Search research articles
Contact Us
Filters
Showing results (21-30 of 32) with videos related to
Page
of 4
Sort By:
Bioorganic & Medicinal Chemistry Letters
|
November 22, 2007
Synthesis and solid-phase purification of anthranilic sulfonamides as CCK-2 ligands
Craig R Woods, Michael D Hack, Brett D Allison, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 10, 2009
Anthranilic sulfonamide CCK1/CCK2 dual receptor antagonists II: tuning of receptor selectivity and in vivo efficacy
Marna Pippel, Kristen Boyce, Hariharan Venkatesan, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
August 9, 2007
3-[5-(3,4-Dichloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-m-tolyl-propionate (JNJ-17156516), a novel, potent, and selective cholecystokinin 1 receptor antagonist: in vitro and in vivo pharmacological comparison with dexloxiglumide
Magda F Morton, Terrance D Barrett, Wen Yan, et al.
Journal of Biomolecular Screening
|
June 6, 2009
Characterization of a robust enzymatic assay for inhibitors of 2-oxoglutarate-dependent hydroxylases
Kimon C Kanelakis, Heather L Palomino, Lina Li, et al.
Blood Advances
|
June 4, 2026
Phase 2a randomized study to evaluate sapablursen in patients with non-transfusion dependent β-thalassemia intermedia
Ali Taher, Michael D Diamantidis, Antonis Kattamis, et al.
Bioorganic & Medicinal Chemistry
|
February 22, 2008
Discovery of potent cholecystokinin-2 receptor antagonists: elucidation of key pharmacophore elements by X-ray crystallographic and NMR conformational analysis
Mark D Rosen, Michael D Hack, Brett D Allison, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
April 16, 2011
JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability
Magda F Morton, Terrance D Barrett, Jamie Freedman, et al.
Journal of Medicinal Chemistry
|
May 18, 2007
Synthesis and biological studies of novel 2-aminoalkylethers as potential antiarrhythmic agents for the conversion of atrial fibrillation
Bertrand Plouvier, Gregory N Beatch, Grace L Jung, et al.
British Journal of Pharmacology
|
May 20, 2015
Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation-induced anaemia in rats
Terrance D Barrett, Heather L Palomino, Theresa I Brondstetter, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 27, 2009
Discovery of the first known small-molecule inhibitors of heme-regulated eukaryotic initiation factor 2alpha (HRI) kinase
Mark D Rosen, Craig R Woods, Steven D Goldberg, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 32) with videos related to
Sort By:
Page
of 4
Bioorganic & Medicinal Chemistry Letters
|
November 22, 2007
Synthesis and solid-phase purification of anthranilic sulfonamides as CCK-2 ligands
Craig R Woods, Michael D Hack, Brett D Allison, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 10, 2009
Anthranilic sulfonamide CCK1/CCK2 dual receptor antagonists II: tuning of receptor selectivity and in vivo efficacy
Marna Pippel, Kristen Boyce, Hariharan Venkatesan, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
August 9, 2007
3-[5-(3,4-Dichloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-m-tolyl-propionate (JNJ-17156516), a novel, potent, and selective cholecystokinin 1 receptor antagonist: in vitro and in vivo pharmacological comparison with dexloxiglumide
Magda F Morton, Terrance D Barrett, Wen Yan, et al.
Journal of Biomolecular Screening
|
June 6, 2009
Characterization of a robust enzymatic assay for inhibitors of 2-oxoglutarate-dependent hydroxylases
Kimon C Kanelakis, Heather L Palomino, Lina Li, et al.
Blood Advances
|
June 4, 2026
Phase 2a randomized study to evaluate sapablursen in patients with non-transfusion dependent β-thalassemia intermedia
Ali Taher, Michael D Diamantidis, Antonis Kattamis, et al.
Bioorganic & Medicinal Chemistry
|
February 22, 2008
Discovery of potent cholecystokinin-2 receptor antagonists: elucidation of key pharmacophore elements by X-ray crystallographic and NMR conformational analysis
Mark D Rosen, Michael D Hack, Brett D Allison, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
April 16, 2011
JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability
Magda F Morton, Terrance D Barrett, Jamie Freedman, et al.
Journal of Medicinal Chemistry
|
May 18, 2007
Synthesis and biological studies of novel 2-aminoalkylethers as potential antiarrhythmic agents for the conversion of atrial fibrillation
Bertrand Plouvier, Gregory N Beatch, Grace L Jung, et al.
British Journal of Pharmacology
|
May 20, 2015
Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation-induced anaemia in rats
Terrance D Barrett, Heather L Palomino, Theresa I Brondstetter, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 27, 2009
Discovery of the first known small-molecule inhibitors of heme-regulated eukaryotic initiation factor 2alpha (HRI) kinase
Mark D Rosen, Craig R Woods, Steven D Goldberg, et al.
Page
of 4